CEO at Novartis at Novartis
1 podcast appearance · 6 clips
a16z Podcast · Vasant Narasimhan
Novartis CEO explains how running multiple business units with different economics forced strategic capital misallocation. He describes the tough trade-offs between optimizing their pharmaceutical business versus investing in generics and devices, ultimately leading to a major corporate restructuring.
Novartis CEO explains how their AI platform called Foundry has transformed their research capabilities, with 3,000 scientists now using AI models to extract data from their data lake in minutes instead of the six months it used to take. He describes this as an incredible leap in pharmaceutical research efficiency that took years to develop and implement.
Novartis CEO explains the harsh reality behind AI drug discovery hype - while everyone expects breakthrough results in two years, the first purely AI-generated drug candidate won't emerge for 8-10 years. He shares how Novartis is partnering with Isomorphic Labs to tackle previously 'undruggable' targets using AlphaFold technology.
Novartis CEO Vasant Narasimhan describes the strategic decision to transform the company into a pure-play biopharmaceuticals business. He explains how they exited the consumer health business through a GSK joint venture and focused on specific therapeutic areas they believed would have the greatest impact.
Novartis CEO Vasant Narasimhan explains how he transformed the pharmaceutical giant from a sprawling conglomerate into four focused companies through strategic spinoffs and divestitures. He details the spin-offs of Alcon and Sandoz, plus the sale of their Roche stake, which collectively unlocked nearly $180 billion in value.
Identifies a specific bottleneck (contracting/IRB reviews) that slows US drug development and connects it to national competitiveness. Practical insight into regulatory reform with clear competitive implications.
a16z Podcast
Novartis CEO Vasant Narasimhan discusses his strategic transformation of the 250-year-old pharmaceutical giant from a conglomerate into a focused medicines company, unlocking $180 billion in value through strategic spin-offs and exits. The conversation covers the company's investments in cutting-edge platform technologies like cell/gene therapies and radioligand treatments, plus how AI is accelerating drug discovery timelines from months to minutes.
